about
Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis.Evaluation of immune infiltration in the colonic mucosa of patients with ipilimumab-related colitisImmune Checkpoint Inhibitor-Induced Colitis: Diagnosis and Management.Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract.Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patients.Clinical assessment of immune-related adverse events.Neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases
P2860
Q33607108-799C65EA-918A-4FE5-8403-401D6504B6B0Q37308199-A266196B-72A7-43D3-B25F-65436736FE68Q39328076-F0E1420D-8C4C-49E2-8053-17F37B2F950FQ47304240-ED992012-4ED8-4FAA-93C0-5A79ED9DD287Q50205173-BEAAC00E-62FC-469E-BDE8-EE4816FF36E5Q55284597-C4E9EDE1-F5DD-441B-BE31-6C5A6DC1C995Q55292659-E55B4241-F581-451B-8E65-D604431A544EQ56889672-FC20516B-B3DF-4FF3-A4DF-A862D8DDA8F7
P2860
description
im Dezember 2015 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 01 December 2015
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в грудні 2015
@uk
name
Infliximab for IPILIMUMAB-Related Colitis--Letter
@en
Infliximab for IPILIMUMAB-Related Colitis--Letter
@nl
type
label
Infliximab for IPILIMUMAB-Related Colitis--Letter
@en
Infliximab for IPILIMUMAB-Related Colitis--Letter
@nl
prefLabel
Infliximab for IPILIMUMAB-Related Colitis--Letter
@en
Infliximab for IPILIMUMAB-Related Colitis--Letter
@nl
P50
P1476
Infliximab for IPILIMUMAB-Related Colitis-Letter
@en
P2093
Gareth Thomas
P304
P356
10.1158/1078-0432.CCR-15-2471
P407
P577
2015-12-01T00:00:00Z